|
|
Volumn 289, Issue 24, 2003, Pages 3229-3230
|
|
Use of Biologics for Rheumatoid Arthritis Tempered by Concerns over Safety, Cost
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
BIOLOGICAL RESPONSE MODIFIER;
ETANERCEPT;
IMMUNOSUPPRESSIVE AGENT;
INFLIXIMAB;
ISONIAZID;
LEFLUNOMIDE;
METHOTREXATE;
NONSTEROID ANTIINFLAMMATORY AGENT;
PYRAZINAMIDE;
RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
ANTIRHEUMATIC AGENT;
IMMUNOLOGICAL ADJUVANT;
TUMOR NECROSIS FACTOR ALPHA;
CANCER RISK;
CLINICAL TRIAL;
DEMYELINATING DISEASE;
DRUG COST;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG RESPONSE;
DRUG SAFETY;
HUMAN;
JOINT DESTRUCTION;
LYMPHOMA;
MYCOSIS;
PNEUMONIA;
PRIORITY JOURNAL;
RESPIRATORY TRACT INFECTION;
REVIEW;
RHEUMATOID ARTHRITIS;
TUBERCULOSIS;
ARTICLE;
DRUG ANTAGONISM;
ECONOMICS;
ADJUVANTS, IMMUNOLOGIC;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
BIOLOGICAL RESPONSE MODIFIERS;
HUMANS;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 0037830125
PISSN: 00987484
EISSN: None
Source Type: Journal
DOI: 10.1001/jama.289.24.3229 Document Type: Review |
|
Times cited : (29)
|
|
References (0)
|